A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)

drug protocol number

D419AC00003

drug sponsor

AstraZeneca

drug study

MEDI4736+Tremelimumab

drug trial site

King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam)

drug status

Ongoing

drug phase